AstraZeneca’s Earnings Beat Shows Momentum, But Can its Pipeline Deliver $80 Billion in Revenue?
AstraZeneca reported strong H1 2026 earnings, with core EPS rising 11% and revenue growth driven by its oncology and rare disease divisions. The company is aiming for $80 billion in annual revenue by 2030, a goal analysts currently view as achievable.
Why it matters
AstraZeneca's performance is a key indicator for the pharmaceutical sector and investor confidence in large-scale drug development pipelines.
AstraZeneca’s Earnings Beat Shows Momentum, But Can its Pipeline Deliver $80 Billion in Revenue? Noor Ul Ain Rehman Sun, August 23, 2026 at 7:54 PM EDT 4 min read AZN +0.91% AZN +0.91% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in